2Schramm TK,Gislason GH,Vaag A,et al.Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes,with or without a previous myocardial infarction:a nationwide study[J].Eur Heart J,2011;32(15):1900-8.
3Mogensen UM,Andersson C,Fosbl EL,et al.Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-a retrospective nationwide study[J].Diabetes Res Clin Pract,2015;107(1):104-12.
4Hassan MH,Abd-Allah GM.Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus[J].Pak J Pharm Sci,2015;28(5):1723-30.
6Holman RR,Paul SK,Bethel MA,et al.10-year follow-up of in tensive glucose control in type 2 diabetes[J].N Engl J Med,2008;359(15):1577-89.
7Hong J,Zhang Y,Lai S,et al.Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease[J].Diabetes Care,2013;36(5):1304-11.
8Preiss D,Lloyd SM,Ford I,et al.Metformin for non-diabetic patients with coronary heart disease(the CAMERA study):a randomised controlled trial[J].Lancet Diabetes Endocrinol,2014;2(2):116-24.
9Skov V,Cangemi C,Gram J,et al.Metformin,but not rosiglitazone,attenuates the increasing plasma levels of a new cardiovascular marker,fibulin-1 ,in patients with type 2 diabetes[J].Diabetes Care,2014;37(3):760-6.
